pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Fintepla
drug · small molecule
save

fenfluramine hydrochloride

Marketedupdated 3mo ago
by UCB SA🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • drugFINTEPLA44 co-mentions · 11 sources
  • tagApproval44 co-mentions · 11 sources
  • tagSmall Molecule22 co-mentions · 11 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 2 investigational indications.

targets

5-hydroxytryptamine receptor 2CSigma non-opioid intracellular receptor 15-hydroxytryptamine receptor 1D

all catalysts(11)

approval · 11
Jun 25, 2020
approval
6y ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
Mar 25, 2022
approval
4y ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
Jun 15, 2022
approval
4y ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
Jan 3, 2023
approval
4y ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
May 30, 2023
approval
3y ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
Sep 14, 2023
approval
3y ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
Sep 14, 2023
approval
3y ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
Dec 11, 2023
approval
3y ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
Apr 2, 2024
approval
2y ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
Apr 8, 2025
approval
1y ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
Oct 15, 2025
approval
10mo ago
FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approval
fenfluramine hydrochloride
→
view all 11 catalysts →

Trials studying fenfluramine hydrochloride

  • phase3A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndromenot yet recruitingn=200
  • phase3A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndromecompletedn=412
  • phase3An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndromecompletedn=375
  • phase3Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).completedn=20
  • phase3A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrometerminatedn=5
  • —ZX008 Expanded Access Protocolapproved for marketing
  • phase3A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndromecompletedn=262

Patent cliff

source: FDA Orange Book
first barrier falls
Jun 25, 2027
318 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (27)

  • Dec 29, 2038patentUS 10452815*PED
  • Feb 2, 2038patentUS 10603290*PED
  • Feb 2, 2038patentUS 11040018*PED
  • Feb 2, 2038patentUS 11406606*PED
  • Feb 2, 2038patentUS 11759440*PED
  • Feb 2, 2038patentUS 11786487*PED
  • Aug 2, 2037method-of-use (U-3347)US 10603290
  • Aug 2, 2037method-of-use (U-3347)US 11040018
  • Aug 2, 2037method-of-use (U-3407)US 11406606
  • Aug 2, 2037method-of-use (U-3694)US 11759440
  • Aug 2, 2037method-of-use (U-3733)US 11786487
  • Jun 20, 2037patentUS 10947183*PED
  • Dec 20, 2036compositionUS 10947183
  • Nov 3, 2033patentUS 10478441*PED
  • Nov 3, 2033patentUS 10478442*PED
  • Nov 3, 2033patentUS 12097206*PED
  • Nov 3, 2033patentUS 9549909*PED
  • Nov 3, 2033patentUS 9603814*PED
  • Nov 3, 2033patentUS 9603815*PED
  • Nov 3, 2033patentUS 9610260*PED
  • May 3, 2033method-of-use (U-2860)US 10478441
  • May 3, 2033method-of-use (U-2860)US 10478442
  • May 3, 2033method-of-use (U-4013)US 12097206
  • May 3, 2033method-of-use (U-2858)US 9549909
  • May 3, 2033method-of-use (U-2858)US 9603814
  • May 3, 2033method-of-use (U-2858)US 9603815
  • May 3, 2033method-of-use (U-2858)US 9610260

FDA exclusivities (4)

  • Sep 25, 2029PEDPediatric (6mo bonus)3.1y
  • Mar 25, 2029ODE-393Orphan Drug (7y)2.6y
  • Dec 25, 2027PEDPediatric (6mo bonus)1.4y
  • Jun 25, 2027ODE-312Orphan Drug (7y)318d

News(0)

no news has mentioned this drug yet

brand
Fintepla
trade names
Fintepla, Ponderax, Ponderax pacaps
generic
fenfluramine hydrochloride
MOA
Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist; Serotonin 1d (5-HT1d) receptor agonist
indication
Unspecified Genetic Disorders
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?